Dr. Sainath Bhethanabhotla, Medical Oncologist
MBBS, MD, DM (Medical Oncology)
Medical Oncologist
Dr. Sainath Bhethanabhotla Appointment and Practice Locations
Survey No.74, Financial District,
Nanakramguda, Hyderabad
Get Directions
OP Timings
Mon - Sat
09:30 am - 02:00 pm
Fee: 750
8-2-596/5, Rd No. 10, Gaffar Khan Colony,
Banjara Hills, Hyderabad
Get Directions
OP Timings
Mon, Wed, Fri
03:00 pm - 05:00 pm
Fee: 900
- Practice Locations (2)
- Profile
- Patient Reviews
- Q&A
- Media
Specializations
Medical Oncologist
Oncologist
Qualifications
- MBBS - Osmania Medical College - 2007 - Hyderabad
- MD - Internal Medicine - All India Institute of Medical Sciences - 2012 - New Delhi
- DM - Medical Oncology - All India Institute of Medical Sciences - 2016 - New Delhi
Experiences
- Senior Resident - Medical Oncology AIIMS - New Delhi
- Resident Super Specialist MNJ Institute of Oncology and Regional Cancer Center - Hyderabad
- Consultant Medical Oncologist Krishna Institute of Medical Sciences
- Consultant Medical Oncologist American Oncology Institute - Hyderabad
- Consultant Medical Oncologist Star Hospitals - Nanakramguda - Currently Working
- Consultant Medical Oncologist Star Hospital - Banjara Hills - Currently Working
Registrations
- 58032 Telangana State Medical Council 2007
Awards and Recognitions
- Abstract Achievement Award at American Society of Hematology Meeting on Hematological Malignancies held in Chicago for the abstract Prognostic Significance of Neutrophil - Lymphocyte Ratio in Advanced Pediatric Hodgkin Lymphoma - A Multicentric Analysis of 186 patients - 2016
- Won Sorel Catherine Prize for Best Post Graduate in Pediatrics for the Year 2012
- Stood 2nd in NNF Gold Medal Paper for the Year 2012(1)
Paper Presentations
- Bhethanabhotla S, Bakhshi S, Reply : Neither Post - Treatment PET-CT Nor Interim PET - CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma, J Nucl Med. 2016 Dec8; IMPACT FACTOR: 7.439
- Bhethanabhotla S, Jain S, Kapoor G, Mahajan A, Chopra A, Vishnubhatla S, Et Al. Outcome of Pediatric Advanced Hodgkin Lymphoma Treated with ABVD and Predictors of Inferior Survival : A Multicenter Study of 186 Patients, Leuk Lymphoma, 2016 Dec 6;1–7, IMPACT FACTOR:2.644
- Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, Et Al, Post - Treatment PET - CT Rather Than Interim PET - CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma : A Prospective Study Comparing PET - CT Versus Conventional Imaging, J Nucl Med. 2016 Oct 6; IMPACT FACTOR: 7.439
- Bhethanabhotla S, Bakhshi S, Presence of Risk Factors Does Not Affect Outcome in Early Stage Pediatric Hodgkin Lymphoma Treated with ABVD. Ann Hematol. 2016 Nov 18; Impact Factor : 2.845
- Taywade SK, Kumar R, Bhethanabhotla S, Bal C. Role of (18) F -FDG PET - CT in Monitoring the Cyclophosphamide Induced Pulmonary Toxicity in Patients with Breast Cancer - 2 Case Reports, Nucl Med Mol Imaging, 2016 Sep;50(3):261–5
- Kakkar A, Rajeshwari M, Bhethanabhotla S, Kaur K, Jain D, Gogia A, Et Al. Primary Diffuse Large B - Cell Lymphoma of the Prostate: A Report of Two Cases with Diagnostic Considerations, J Cancer Res Ther. 2015 Dec;11(4):977–9, Impact Factor: 0.8459
- Gajendra S, Gogia A, Tanwar P, Sahoo MK, Bhethanabhotla S, Durgapal P, Et Al. Synchronous Metastatic Pulmonary Adenocarcinoma with Small Cell Lymphoma. Leuk Lymphoma. 2014 Jul;55(7):1678–80. IMPACT FACTOR: 2.644
- Bhethanabhotla S, Thukral A, Sankar MJ, Agarwal R, Paul VK, Deorari AK. Effect of Position of Infant During Phototherapy in Management of Hyperbilirubinemia in Late Preterm and Term Neonates: A Randomized Controlled Trial. J Perinatol. 2013 Oct;33(10):795–9. IMPACT FACTOR: 2.183
- Kumar L, Boya RR, Pai R, Harish P, Mookerjee A, Sainath B, Et Al. Autologous Stem Cell Transplantation for Multiple Myeloma: Long-Term Results. The National Medical Journal of India. 2016 Jul 1;29(4):192. IMPACT FACTOR: 0.786
- Bhethanabhotla, S., Tiwari, A., Sharma, M.C. Et Al. Prognostic Significance of IL-6 In Hodgkin Lymphoma. Indian J Pediatr. 2019 Mar 4;Online First. IMPACT FACTOR: 1.046
- Patel A, Tannock I, Bhethanabhola S, Srivastva P, Biswas B, Et Al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is it Practice Changing Facts and Facets.JCO Glob Oncol. 2020 Mar;6:382-386. IMPACT FACTOR:1.79
Report an error
Dr. Sainath Bhethanabhotla, Medical Oncologist Reviews
No feedback available for this Doctor.
Be the first to write a review.
Question & Answers by Dr. Sainath Bhethanabhotla
No Question & Answers by this doctor.
Media from Dr. Sainath Bhethanabhotla
No Videos updated by this doctor.
